Hisse Senetlerindeki Sıralama
#41692
Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in... Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and infectious diseases, particularly those caused by coronaviruses. The company's pipeline features several key programs: UB-311 is a Phase 2 clinical trial candidate targeting toxic aggregated amyloid-beta proteins in the brain, aiming to treat Alzheimer's disease. UB-312, currently in Phase 1 clinical trials, is an investigational therapy designed to address Parkinson's disease and other synucleinopathies, including Lewy body dementia and multiple system atrophy, by targeting detrimental aggregated alpha-synuclein. An anti-tau product candidate is also under development for various neurodegenerative conditions, such as Alzheimer's disease. UB-313 is being developed to alleviate migraines by modulating calcitonin gene-related peptide. An anti-PCSK9 candidate aims to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events by targeting proprotein convertase subtilisin/kexin type 9 serine protease. In the infectious disease segment, UB-612 is a Phase 3 clinical-stage candidate engineered to neutralize the SARS-CoV-2 virus.
Hisse Fiyatı
$0.0001
Son senkronizasyon: 2026-08-11
Ticaret Vaxxinity, Inc. (VAXX)
Vaxxinity, Inc. (VAXX) için gelir
Aug 2026 itibarıyla gelir TTM: 0
Vaxxinity, Inc. şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) 0'dir. 2026 yılında şirketin geliri 0 önceki yıla eşit 2026 yılındaki 0 gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Vaxxinity, Inc. için 2026 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
| Yıl |
Gelir |
Değiştir |
|
Sağlanan tarihler için yeterli veri yok. |
Benzer şirketler veya rakiplerin geliri
| Şirket |
Gelir |
Gelir Farkı |
Ülke |
|
|
$12.62B |
-
|
US
|
|
|
$6.02B |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
$10.11B |
-
|
BE
|
|
|
- |
-
|
KR
|